BCG Baden-Baden Cosmetics filed for insolvency — German skincare brand ran out of credit

BCG Baden-Baden Cosmetics Group was a German multi-brand cosmetics company founded in the 1940s and headquartered in Baden-Baden. It owned well-known skincare brands including Sans Soucis, Biodroga, Dr. Scheller, and Bio:Vegane. The company covered the entire value chain — from R&D and production to global distribution — and exported to around 70 countries. It employed approximately 160 people and was considered a leading independent mid-sized cosmetics manufacturer in Germany.

On March 26, 2026, the company filed for preliminary self-administration insolvency proceedings at the Local Court of Baden-Baden. The court approved the application, allowing the company to retain control of its restructuring under court supervision. The move was proactive rather than reactive: the company was operationally sound and profitable, but legacy financial obligations from earlier years made it impossible to extend existing credit lines, creating a liquidity bottleneck.

CEO Hermann Crux, who had led the company for 11 years, remained in charge, supported by restructuring expert Marc-Philippe Hornung from the law firm SZA Schilling, Zutt & Anschütz, who was appointed as an additional managing director. The court appointed Dr. Dirk Pehl of Schultze & Braun as preliminary administrator to safeguard creditor interests. The goal was a sustainable financial restructuring that would preserve the company's operational strength.

The business continued operating without restrictions during the proceedings. Customer orders, production, and supply chains were unaffected. Employee salaries were secured for up to three months through statutory insolvency compensation. The company's management expressed confidence in the future, stating that the insolvency was purely a financing issue, not an operational one.

Filed for self-administration insolvency to restructure under court supervision, keeping operations running and salaries secured while resolving the credit bottleneck.

Legacy financial obligations from earlier years made it impossible to extend existing credit lines, creating a liquidity bottleneck despite the company being operationally sound.

The company lacked the financial flexibility to absorb the shock of a credit line not being renewed, leaving insolvency as the only restructuring option.

As a mid-sized independent manufacturer, BCG did not have the balance sheet to absorb financial shocks, and its creditworthiness was tied to its legacy debt burden.

Earlier acquisitions had left the company with debt that could not be serviced without bank financing, and when banks declined to renew, the structure collapsed.

A profitable company can be driven to insolvency by past financial decisions. BCG was competitive and sound, but legacy debts that blocked credit renewal forced it into court protection.

BCG Baden-Baden Cosmetics Group entered self-administration insolvency proceedings in March 2026. The business continued operating normally, with salaries secured for three months. The restructuring aimed to stabilise financing and preserve the company as a going concern. The Sans Soucis, Biodroga, Dr. Scheller, and Bio:Vegane brands remained on the market during the proceedings.